Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery, lower cost, and an opportunity for earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's initial lead product candidates, PTG-100 and PTG-200, are based on this approach, and the company believes they have the potential to transform the existing treatment paradigm for IBD, a GI disease consisting primarily of ulcerative colitis and Crohn's disease.
Founder: Mark Symythe
CEO: Dinesh Patel
CMO (Marketing): Richard Shames
CFO: Tom O’Neil
CSO (Scientific): David Liu
Please click here for Protagonist Therapeutics job opportunities.
Please click here for clinical trial information.
183 articles with Protagonist Therapeutics, Inc.
Key Patent Issues Covering Protagonist' Oral Peptide IL-23 Receptor Antagonists, Including The Development Candidate PTG-200
Protagonist Presents Data On Oral Peptide Drug Candidates At European Crohn's And Colitis Organization (ECCO) Congress
Protagonist Release: Pharma Initiates Phase 2b Study Of Oral Drug Candidate PTG-100 In Ulcerative Colitis
Key Patent Is Issued Covering Protagonist' Alpha4Beta7 Integrin Peptide Inhibitors Including Oral Drug Candidate PTG-100
Protagonist Therapeutics Receives SBIR Funding For The Development Of Injectable Hepcidin Mimetics For Treatment Of Iron Overload Disorders
Protagonist Therapeutics Receives SBIR Funding For Oral IL-23 Receptor Antagonists For Treatment Of Inflammatory Bowel Diseases
Protagonist Therapeutics Closes 2nd Tranche Of $18 Million Series B For Advancing Development Candidate To Clinical Trials In 2015
Protagonist Therapeutics Expands Series B Financing to $18 Million With Addition of $4 Million From Pharmstandard